Outcome according to residual disease (surgeon's report vs pre‐chemotherapy imaging) in patients with bevacizumab‐treated ovarian cancer: Analysis of the ROSiA study

Abstract

Background and Objectives:The single-arm ROSiA study evaluated frontline bevacizumab for advanced ovarian cancer. We explored how discordant surgically and radiologically assessed postoperative residual disease affects outcomes. Methods: After debulking surgery, 1021 patients received 4 to 8 cycles of carboplatin-paclitaxel plus bevacizumab until progression or up to 24 months. The primary endpoint was safety; progression-free survival (PFS) was a secondary endpoint. We performed post hoc exploratory PFS analyses in four subgroups: surgeon-reported no visible residuum (NVR) without target lesions; surgeon-reported NVR with target lesions; macroscopic (≤1 cm) residuum; and >1 cm residuum. Results: Surgical and radiological assessments were concordant in 94% of patients; 61 patients (6%; 21% of those with surgeon-reported NVR) had NVR with target lesions. Median PFS was numerically longest in patients with concordant surgically/ radiologically assessed NVR (35.5 months), intermediate for surgeon-reported NVR with target lesions (31.8 months), and shortest for visible residuum (27.9 and 20.2 months for visible residuum ≤1 and >1 cm, respectively). One-year and 2-year PFS rates showed the same pattern. Conclusions: These analyses suggest that prognosis is potentially worse in patients with radiologically detected target lesions despite surgeon-reported NVR compared with concordant NVR by both assessment methods. Postsurgical imaging may add valuable prognostic information. K E Y W O R D S bevacizumab, imaging, ovarian cancer, progression-free survival, visible residuum How to cite this article: Korach J, Colombo N, Mendiola C, et al. Outcome according to residual disease (surgeon's report vs pre-chemotherapy imaging) in patients with bevacizumabtreated ovarian cancer: Analysis of the ROSiA study. J Surg Oncol. 2019;120:786-793. https://doi.

Effects of Laparoscopic Hyperthermic Perfusion Therapy Combined with Adjuvant Treatment of Compound Yew Capsule on Ovarian Blood Flow Parameters and Immune Function in Patients with Ovarian Cancer

“…A large number of tumor cells will be killed upon exposure to this range of temperature. Fortunately, normal cells can tolerate this temperature range, permitting therapy to perform efficiently and effectively against tumors [26][27][28]. Although laparoscopic hyperthermic perfusion therapy emanates a desirable clinical effect, the single treatment remains unsatisfactory.…”

Role of front-line bevacizumab in advanced ovarian cancer: the OSCAR study

“…Furthermore, in the ROSiA study, 23% of patients had stage I–IIIA disease, in contrast to OSCAR and OTILIA, which included only patients with stage IIIB–IV disease. Surgical differences were also apparent between countries: in the German OTILIA and global ROSiA studies, 94% (A Wegenaer, 2019, personal communication) and 95% of patients, respectively, underwent debulking surgery, and there was no visible residual disease after primary debulking surgery in 27% and 28% of patients, respectively,7 9 15 compared with 57% undergoing surgery and only 4% with no visible residual disease in the OSCAR study.…”

<p>Development of Drug Dual-Carriers Delivery System with Mitochondria-Targeted and pH/Heat Responsive Capacity for Synergistic Photothermal-Chemotherapy of Ovarian Cancer</p>

“…Common methods for the treatment of ovarian cancer mainly include surgery and systemic chemotherapy. [1][2][3] However, the treatment effect is still not ideal and recurrence is high. Additionally, currently used chemotherapy drugs have some disadvantages such as poor water solubility, rapid elimination of small molecules, lack of specific targeting, and systemic toxicity caused by large doses.…”